Plant Name: Phaius mishmensis
Taxonomic Information:
Plant ID: NPO4147
Plant Latin Name: Phaius mishmensis
Taxonomy Genus: Phaius
Taxonomy Family: Orchidaceae
Plant External Links:
NCBI TaxonomyDB:
679631
Plant-of-the-World-Online:
650444-1
Used in Medicines:
Unknown.
Geographical Distribution:
Bangladesh; Myanmar; Philippines; India; Vietnam; China; Laos; Thailand; Taiwan
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| PTGS2; ALOX5; | |
| IDO1; | |
| RAB9A; LMNA; NPC1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | IDO1 | Indoleamine 2,3-dioxygenase | P14902 | CHEMBL4685 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0032501; multicellular organismal process | GO:0002532; production of molecular mediator involved in inflammatory response | 2.250E-06 | 1.225E-02 | ALOX5, IDO1 |
| BP | GO:0008152; metabolic process | GO:0032787; monocarboxylic acid metabolic process | 5.385E-06 | 2.345E-02 | ALOX5, IDO1, NPC1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 9.631E-06 | 3.292E-02 | ALOX5, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0046456; icosanoid biosynthetic process | 5.329E-05 | 9.166E-02 | ALOX5, PTGS2 |
| BP | GO:0009987; cellular process | GO:0060548; negative regulation of cell death | 8.188E-05 | 1.180E-01 | IDO1, LMNA, NPC1, PTGS2 |
| CC | GO:0016020; membrane | GO:0031090; organelle membrane | 2.903E-04 | 2.416E-01 | ALOX5, LMNA, NPC1, PTGS2, RAB9A |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 6.212E-04 | 3.411E-01 | PTGS2 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 6.423E-04 | 3.411E-01 | IDO1, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 9.316E-04 | 3.651E-01 | PTGS2 |
| CC | GO:0044464; cell part | GO:0032421; stereocilium bundle | 1.552E-03 | 4.966E-01 | IDO1 |
| CC | GO:0044464; cell part | GO:0005641; nuclear envelope lumen | 2.483E-03 | 5.691E-01 | ALOX5 |
| CC | GO:0044464; cell part | GO:0005764; lysosome | 2.896E-03 | 5.875E-01 | NPC1, RAB9A |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; ALOX5; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; ALOX5; |
| NA: NA | Rheumatold arthritis | NA | PTGS2; |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2; |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; |
| NA: NA | Joint and muscular pain | NA | PTGS2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; ALOX5; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; ALOX5; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; ALOX5; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; ALOX5; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
